Katherine Davis

1 week ago | axios.com | Katherine Davis

Axios Pro Exclusive ContentIllustration: Aïda Amer/AxiosVivodyne, a San Francisco-based startup using lab-grown human tissues to discover and develop drugs, raised $40 million in a Series A led by Khosla Ventures. Why it matters: Vivodyne says demand is "surging" from pharma clients following the FDA's announced plans to "phase out" animal testing requirements in drug development. Follow the money: New investors include Lingotto Investment Management, Helena Capital and Fortius Ventures.

1 week ago | axios.com | Katherine Davis

Axios Pro Exclusive ContentIllustration: Axios VisualsGlycoEra, a Swiss biotech startup developing autoimmune disease treatments, raised $130 million in a Series B round. Why it matters: Immunology and inflammation startups continue to attract investor attention as there's significant unmet patient need. Follow the money: Novo Holdings led the round, and was joined by Catalio Capital Management, LifeArc Ventures, QIA Sofinnova Partners, Roche Ventures and Bristol Myers Squibb.

2 weeks ago | axios.com | Katherine Davis

Fore Biotherapeutics plans to submit its cancer drug candidate to the FDA for approval in the second half of next year, CEO Bill Hinshaw tells Axios. Why it matters: As the company hits milestones, it will likely need to fundraise again before 2027, Hinshaw says. Driving the news: Philadelphia-based Fore raised $38 million in a Series D-2 on Thursday, growing the D round to $113 million and bringing the company's total funding to about $250 million.

2 weeks ago | axios.com | Katherine Davis

DataHub, an open-source metadata platform, raised a $35 million Series B round, founders Swaroop Jagadish and Shirshanka Das tell Axios exclusively. Why it matters: The round reflects continued VC enthusiasm for AI, even as investors remain highly selective. Follow the money: The Series B was led by Bessemer Venture Partners, with participation from 8VC, Tru Arrow, SineWave, In-Q-Tel and Zero Prime. DataHub, formerly known as Acryl Data, has now raised $65 million since its inception in 2021.

2 weeks ago | axios.com | Katherine Davis

Biostate AI, a generative AI startup using RNA sequencing data, raised $12 million in Series A funding, founders David Zhang and Ashwin Gopinath tell Axios exclusively. Why it matters: The company focuses on patient treatments rather than drug development. How it works: Biostate is building a generative AI service based on RNA sequencing data that predicts how human diseases behave, evolve, progress and respond to different drugs and treatments.